605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III
0 activities
Ancestral L-Asparaginases Are Cytotoxic Against ALL Cell Lines with Predicted Reduced Immunogenicity
1 activities
Ancestral L-Asparaginases Are Cytotoxic Against ALL Cell Lines with Predicted Reduced Immunogenicity
CT1113, a Potent, Oral Small Molecule Inhibitor of USP25, Demonstrates Anti-Tumor Activity in Ph-Positive Acute Lymphoblastic Leukaemia
1 activities
CT1113, a Potent, Oral Small Molecule Inhibitor of USP25, Demonstrates Anti-Tumor Activity in Ph-Positive Acute Lymphoblastic Leukaemia
Dexamethasone Is More Potent Than Prednisone in B-Lymphoblastic Leukemia Despite Dose Adjustment
1 activities
Dexamethasone Is More Potent Than Prednisone in B-Lymphoblastic Leukemia Despite Dose Adjustment
Infiltration of Innate Immune Cells into Tumors By Polatuzumab Vedotin Treatment Contributes to Its Antitumor Effect in Xenograft and Syngeneic Mouse Models
1 activities
Infiltration of Innate Immune Cells into Tumors By Polatuzumab Vedotin Treatment Contributes to Its Antitumor Effect in Xenograft and Syngeneic Mouse Models
Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
1 activities
Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
Metabolic and Cell Cycle Proteins As Novel Targets of Selinexor Activity in Diffuse Large B Cell Lymphoma
1 activities
Metabolic and Cell Cycle Proteins As Novel Targets of Selinexor Activity in Diffuse Large B Cell Lymphoma
Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
1 activities
Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
Revealing the Synergistic Potential of Mosunetuzumab Plus Polatuzumab Vedotin through CD20 Upregulation
1 activities
Revealing the Synergistic Potential of Mosunetuzumab Plus Polatuzumab Vedotin through CD20 Upregulation
Selinexor Induces DLBCL Cell Senescence Mediated By USP1/MDMX/p53 Axis
1 activities
Selinexor Induces DLBCL Cell Senescence Mediated By USP1/MDMX/p53 Axis
Tgrx-678 Penetrates Blood-Brain Barrier and Exhibits Preclinical Anti-Tumor Activity in Murine Ph+ CNS Leukemia and ALL Models
1 activities
Tgrx-678 Penetrates Blood-Brain Barrier and Exhibits Preclinical Anti-Tumor Activity in Murine Ph+ CNS Leukemia and ALL Models
The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities
1 activities
The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities
Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade
1 activities
Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade
Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma
1 activities
Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma